Ayuda
Ir al contenido

Dialnet


Resumen de The Use of Biologic Agents in Pregnancy and Breastfeeding

Sara Horst, Sunanda Kane

  • Biologic therapies, including anti–tumor necrosis factor antibody therapy and anti-integrin antibodies, are currently approved for the treatment of and are increasingly being used in patients with moderate to severe inflammatory bowel disease, including Crohn disease and ulcerative colitis. Because patients who require these medications are often in their child-bearing years, knowledge of the safety of these medications before and after pregnancy is imperative. This article summarizes the available data regarding the use of biologic therapy during and after pregnancy, highlighting such issues as safety for mother and newborn, length of medication use during pregnancy, and breastfeeding after pregnancy while on biologic therapy.


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus